Abstract
Background and Aims : Homozygous familial hypercholesterolemia (HoFH) is a genetic disorder characterized by extremely high levels of circulating low-density lipoprotein cholesterol (LDL-C). Lomitapide is a microsomal transfer protein inhibitor that has demonstrated LDL receptor-independent lipid-lowering efficacy in HoFH patients in long-term clinical trials and real-world studies.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
